Author Index

Aduma, P.J., Gupta, S.V. and De Clercq, E., Antiherpes virus activity and effect on deoxyribonucleoside triphosphate pools of (E)-5-(2-bromovinyl)-2′-deoxycytidine in combination with deaminase inhibitors, 111
Alaghamandan, H.A., see Smee, D.F., 1
Alaghamandan, H.A., see Smee, D.F., 91
Alba, A.P.C., see De Fazio, G., 219
Alteri, E., see Lazdins, J., 175

Babu, J.R., see Schinazi, R.F., 265
Bartlett, M.L., see Smee, D.F., 1
Bernaerts, R., see Merta, A., 209
Bernstein, D.I., see Reuman, P.D., 103
Bernstein, D.I., see Stanberry, L.R., 227
Brachwitz, H., see Matthes, E., 273
Braitman, A., see Field, A.K., 43
Bravo, F., see Stanberry, L.R., 227
Burgin, C., see Lazdins, J., 175
Burke, R.L., see Ho, R.J.Y., 187

Cannon, D.L., see Schinazi, R.F., 265
Černý, J., Votruba, I., Vonka, V., Rosenberg, I., Otmar, M. and Holý, A., Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase, 253
Černý, J., see Holý, A., 295
Ceruzzi, M., see Draper, K.G., 151
Childs, F., see Stanberry, L.R., 227
Chou, T.-C., see Soike, K.F., 165
Chu, C.K., see Schinazi, R.F., 265
Clark, J.M., see Field, A.K., 43
Cload, P.A., see Mulder, J.W., 127
Colacino, J.M., see Tang, J., 313
Coutinho, R.A., see Mulder, J.W., 127

Dalrymple, J.M., see Malinski, F.J., 139
De Clercq, E., see Aduma, P.J., 111
De Clercq, E., see De Fazio, G., 219
De Clercq, E., see Holý, A., 295
De Fazio, G., Alba, A.P.C., Vicente, M. and De Clercq, E., Antiviral activity of S-adenosylhomocysteine hydrolase inhibitors against plant viruses, 219
De Wolf, F., see Mulder, J.W., 127
Desideri, N., see Superti, F., 201
Donelli, G., see Superti, F., 201
Draper, K.G., Ceruzzi, M., Kmetz, M.E. and Sturzenbecker, L.J., Complementary oligonucleotide sequence inhibits both Vmw65 gene expression and replication of herpes simplex virus, 151

Eghafona, N.O. and Emejuaiwe, S.O., (Avid) rosette-forming cells as evidence for cellular immunity following measles virus vaccination in monkeys: correlation with the presence of haemagglutination inhibitory antibodies, 75
Emejuaiwe, S.O., see Eghafona, N.O., 75
Eriksson, B.F.H., see Schinazi, R.F., 265

Feng, J.S., see Li, S.B., 237
Fiddian, A.P., see Mulder, J.W., 127
Field, A.K., Tuomari, A.V., McGeever-Rubin, B., Terry, B.J., Mazina, K.E., Haffey, M.L., Hagen, M.E., Clark, J.M., Braitman, A., Slusarchyk, W.A., Young, M.G. and Zahler, R., ()-(1α,2β,3α)-9-[23-bis(hydroxymethyl)-cyclobutyl]guanine [()-BHCG or SQ 33054]: a potent and selective inhibitor of herpesviruses, 43
Fong, C.K.Y., see Li, S.B., 237
Fox, J.J., see Soike, K.F., 165

Gangemi, J.D., see Lazdins, J., 175
Gloff, C.A., see Soike, K.F., 165
Goudsmit, J., see Mulder, J.W., 127
Gupta, S.V., see Aduma, P.J., 111

Haffey, M.L., see Field, A.K., 43
Hagen, M.E., see Field, A.K., 43
Harada, H., see Nagata, K., 11
Harrison, C.J., see Stanberry, L.R., 227
Hasegawa, A., see Ikeda, S., 327
Hasty, S.E., see Malinski, F.J., 139
Ho, R.J.Y., Burke, R.L. and Merigan, T.C., Physical and biological characterization of antigen presenting liposome formulations: relative efficacy for the treatment of recurrent genital HSV-2 in guinea pigs, 187
Holý, A., Votruba, I., Merta, A., Černý, J., Vesely, J., Vlach, J., Sedivá, K., Rosenberg, I., Otmar, M., Hřebabecky, H., Trávnicek, M., Vonka, V., Snoeck, R. and De Clercq, E., Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro, 295
Holý, A., see Černý, J., 253
Holý, A., see Merta, A., 209

Holý, A., see Votruba, I., 287
Homma, J.Y., see Ikeda, S., 327
Horisberger, M.A., Schrenk, R., Staiger, S., Leyvraz, A.R. and Martinod, S., Induction of Mx-related protein in cat peripheral blood mononuclear cells after administration of recombinant human interferon hybrid, 53
Hřebabecky, H., see Holý, A., 295
Hřebabecky, H., see Merta, A., 209
Hřebabecky, H., see Votruba, I., 287
Hsiung, G.D., see Li, S.B., 237

Ikeda, S., Nishimura, C., Matsuura, M., Homma, J.Y., Kiso, M. and Hasegawa, A., Effect of acyl substituents of synthetic lipid A-subunit analogues on their immunomodulating antiviral activity (Short Communication), 327
Ishihama, A., see Nagata, K., 11
Ishitsuka, H., see Ninomiya, Y., 61

Jin, A., see Smee, D.F., 91
Jolley, W.B., see Smee, D.F., 91
Jones, M.M., see Smee, D.F., 1

Keely, S.P., see Reuman, P.D., 103
Kiso, M., see Ikeda, S., 327
Kmetz, M.E., see Draper, K.G., 151
Konno, K., see Nagata, K., 11
Kovacs, T., see Subramanian, M., 81

Lange, J.M.A., see Mulder, J.W., 127
Langen, P., see Matthes, E., 273
Larsen, S.H., see Tang, J., 313
Lazdins, J., Alteri, E., Woods Cook, K., Burgin, C. and Gangemi, J.D., Use of human monocytes in the evaluation of antiviral drugs: quantitation of HSV-1 cytopatic effects, 175
Lenard, J., see Subramanian, M., 81
Lesiak, K., see Subramanian, M., 81
Leyvraz, A.R., see Horisberger, M.A., 53
Li, S.B., Yang, Z.H., Feng, J.S., Fong, C.K.Y., Lucia, H.L. and Hsiung, G.D., Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs, 237
Lucia, H.L., see Li, S.B., 237

Maidhof, A., see Matthes, E., 273
Malinski, F.J., Hasty, S.E., Ussery, M.A. and Dalrymple, J.M., Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys, 139
Martinod, S., see Horisberger, M.A., 53
Marziano, M.L., see Superti, F., 201
Matsuura, M., see Ikeda, S., 327
Matthes, E., Langen, P., Brachwitz, H., Schröder, H.C., Maidhof, A., Weiler, B.E., Renneisen, K. and Müller, W.E.G., Alteration of DNA topoisomerase II activity during infection of H9 cells by human immunodeficiency virus type 1 in vitro: a target for potential therapeutic agents, 273
Mazina, K.E., see Field, A.K., 43
McGeever-Rubin, B., see Field, A.K., 43
Merigan, T.C., see Ho, R.J.Y., 187
Merta, A., Votruba, I., Rosenberg, I., Otmar, M., Hřebabecky, H., Bernaerts, R. and Holý, A., Inhibition of herpes simplex virus DNA polymerase by diphosphates of acrylic phosphonylmethoxyalkyl nucleotide analogues, 209
Merta, A., see Holý, A., 295
Merta, A., see Votruba, I., 287
Mulder, J.W., De Wolf, F., Goudsmit, J., Cload, P.A., Coutinho, R.A., Fiddian, A.P., Schellekens, P.T., Van der Noordaa, J. and Lange, J.M.A., Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects, 127
Müller, W.E.G., see Matthes, E., 273

Nagata, K., Sakagami, H., Harada, H., Nonoyama, M., Ishihama, A. and Konno, K., Inhibition of influenza virus infection by pine cone antitumor substances, 11
Nasr, M., see Schinazi, R.F., 265
Ninomiya, Y., Shimma, N. and Ishitsuka, H., Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides, 61
Nishimura, C., see Ikeda, S., 327
Nonoyama, M., see Nagata, K., 11

Orsi, N., see Superti, F., 201
Oswald, B.J., see Schinazi, R.F., 265
Otmar, M., see Černý, J., 253
Otmar, M., see Holý, A., 295
Otmar, M., see Merta, A., 209
Otmar, M., see Votruba, I., 287

Reece, A.L., see Stanberry, L.R., 227
Renneisen, K., see Matthes, E., 273
Reuman, P.D., Bernstein, D.I., Keely, S.P., Sherwood, J.R., Young, E.C. and Schiff, G.M., Influenza-specific ELISA IgA and IgG predict severity of influenza disease in subjects prescreened with hemagglutination inhibition, 103
Revankar, G.R., see Smee, D.F., 1
Robins, R.K., see Smee, D.F., 1
Rosenberg, I., see Černý, J., 253

Rosenberg, I., see Holý, A., 295
Rosenberg, I., see Merta, A., 209
Rosenberg, I., see Votruba, I., 287

Saalmann, V., see Schinazi, R.F., 265
Sakagami, H., see Nagata, K., 11
Schellekens, P.T., see Mulder, J.W., 127
Schiff, G.M., see Reuman, P.D., 103
Schinazi, R.F., Chu, C.K., Babu, J.R., Oswald, B.J., Saalmann, V., Cannon, D.L., Eriksson, B.F.H. and Nasr, M., Anthraquinones as a new class of antiviral agents against human immunodeficiency virus (Short Communication), 265
Schrenk, R., see Horisberger, M.A., 53
Schröder, H.C., see Matthes, E., 273
Sedivá, K., see Holý, A., 295
Seganti, L., see Superti, F., 201
Sharma, B.S., see Smee, D.F., 91
Sherwood, J.R., see Reuman, P.D., 103
Shimma, N., see Ninomiya, Y., 61
Slusarchyk, W.A., see Field, A.K., 43
Smee, D.F., Alaghamandan, H.A., Jin, A., Sharma, B.S. and Jolley, W.B., Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice, 91
Smee, D.F., Bartlett, M.L., Alaghamandan, H.A., Jones, M.M., Revankar, G.R. and Robins, R.K., 4,6-Dibenzamidopyrazolo[3,4-d]pyrimidine is a highly selective inhibitor of cytomegalovirus adsorption to cells, 1
Snoeck, R., see Holý, A., 295
Soike, K.F., Chou, T.-C., Fox, J.J., Watanabe, K.A. and Gloff, C.A., Inhibition of Simian varicella virus infection of monkeys by 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-β, 165
Spitzer, W., see Tang, J., 313
Staiger, S., see Horisberger, M.A., 53
Stanberry, L.R., Harrison, C.J., Bravo, F., Childs, F., Reece, A.L. and Bernstein, D.I., Recurrent genital herpes in the guinea pig augmented by ultraviolet irradiation: effects of treatment with acyclovir, 227
Stein, M.L., see Superti, F., 201
Sturzenbecker, L.J., see Draper, K.G., 151
Subramanian, M., Kovacs, T., Lesiak, K., Torrence, P.F. and Lenard, J., Inhibition of the RNA polymerase of vesicular stomatitis virus ppp5′A2′p5′A and related compounds, 81
Superti, F., Seganti, L., Orsi, N., Desideri, N., Stein, M.L., Tinari, A., Marziano, M.L. and Donelli, G., In vitro effect of synthetic flavanoids on astrovirus infection (Short Communication), 201
Sühnel, J., Evaluation of synergism or antagonism for the combined action of antiviral agents, 23

Tang, J., Colacino, J.M., Larsen, S.H. and Spitzer, W., Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses, 313
Terry, B.J., see Field, A.K., 43
Tinari, A., see Superti, F., 201
Torrence, P.F., see Subramanian, M., 81
Trávnicek, M., see Holý, A., 295
Trávnicek, M., see Votruba, I., 287
Tuomari, A.V., see Field, A.K., 43

Ussery, M.A., see Malinski, F.J., 139

Van der Noordaa, J., see Mulder, J.W., 127
Vesely, J., see Holý, A., 295
Vicente, M., see De Fazio, G., 219
Vlach, J., see Holý, A., 295
Vonka, V., see Černý, J., 253
Vonka, V., see Holý, A., 295
Votruba, I., Trávnicek, M., Rosenberg, I., Otmar, M., Merta, A., Hřebabecky, H. and Holý, A., Inhibition of avian myeloblastosis virus reverse transcriptase by diphosphates of acyclic phosphonylmethyl nucleotide analogues, 287
Votruba, I., see Černý, J., 253
Votruba, I., see Holý, A., 295
Votruba, I., see Merta, A., 209

Watanabe, K.A., see Soike, K.F., 165
Weiler, B.E., see Matthes, E., 273
Woods Cook, K., see Lazdins, J., 175

Yang, Z.H., see Li, S.B., 237
Young, E.C., see Reuman, P.D., 103
Young, M.G., see Field, A.K., 43

Zahler, R., see Field, A.K., 43

Subjec Index

Acyclic nucleotide analogue, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivates, N-(2-phosphonylmethoxyethyl) derivative, HPMPA, HPMPC, PMEA, 295
Acyclovir, Recurrent genital herpes, Herpes simplex virus, Guinea pig model, 227
(RS)-AHPA, SAH hydrolase inhibitor, (RS)-DHPA, C-c3Ado, Plant virus, TMV, PVX, 219
Antagonism, Synergism, Antiviral combination experiment, Isobole method, Mathematical modeling, 23
Anthraquinone, Anti-HIV-1 activity, Reverse transcriptase, Hypericin, 265
Anti-HIV-1 activity, Anthraquinone, Reverse transcriptase, Hypericin, 265
Antigen presentation, Immunotherapy, HSV, Liposome, Recurrence, 187
Antiherpes activity, (E)-5-(2-bromovinyl)-2′-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), dNTP pool, HSV-infected cell, 111
Antirhinovirus agent, Ro 09-0410, Chalcone amide, Binding site, Drug resitant HRV-2 subline, 61
Antiviral combination experiment, Synergism, Antagonism, Isobole method, Mathematical modeling, 23
Antiviral agent, Cytomegalovirus infection, Nucleoside analog, HPMPC, Cultured cell, Guinea pig, 237
2-5 As, Dinucleotide, Vesicular stomatitis virus, RNA polymerase, Inhibition of RNA synthesis, 81
Astrovirus, Synthetic flavanoid, 201
Asymptomatic HIV infection, HIV-1 p24 antigenemia, Zidovudine treatment, 127
Avian myeloblastosis virus, Reverse transcriptase, Retrovirus, PMEA, 287

()-BHCG, HSV-1, HSV-2, 43
Binding site, Antirhinovirus agent, Ro 09-0410, Chalcone amide, Drug resitant HRV-2 subline, 61

C-c3Ado, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, Plant virus, TMV, PVX, 219
Cat Mx protein, Interferon, Feline viral disease, 53
Cell-mediated immunity, Measles virus, 75
Chalcone amide, Antirhinovirus agent, Ro 09-0410, Binding site, Drug resitant HRV-2 subline, 61
CMV receptor, Human CMV, Mouse CMV, Monkey CMV, 1
Cultured cell, Cytomegalovirus infection, Antiviral agent, Nucleoside analog, HPMPC, Guinea pig, 237
Cytomegalovirus infection, Antiviral agent, Nucleoside analog, HPMPC, Cultured cell, Guinea pig, 237

(RS)-DHPA, SAH hydrolase inhibitor, (RS)-AHPA, C-c3Ado, Plant virus, TMV, PVX, 219
Dengue, Ribavirin, Rhesus monkey, 139
Differentiation, Human monocyte, Herpes simplex virus type 1, Interferon-, Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
Dinucleotide, 2-5 As, Vesicular stomatitis virus, RNA polymerase, Inhibition of RNA synthesis, 81
DNA polymerase inhibition, Herpes simplex virus, Phosphonylmethoxyalkylpurine,-pyrimidine, HPMPA, PMEA, 209
DNA topoisomerase II activity, Hg cells, HIV-1, 273
Drug resitant HRV-2 subline, Antirhinovirus agent, Ro 09-0410, Chalcone amide, Binding site, 61
Drug screening, Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon-α, Poly I:C-LC, acyclovir, Viability index, 175

(E)-5-(2-bromovinyl)-2′-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Antiherpes activity, dNTP pool, HSV-infected cell, 111
Enveloped virus, Hypericin, Pseudophypericin, Virucidal agent, Non-enveloped virus, 313

FEAU, Hu rIFN, Simian varicella virus, Monkey, 165
Feline viral disease, Interferon, Cat Mx protein, 53

Guanosine analog, Nucleoside analog, Immune modulator, 91
Guinea pig model, Acyclovir, Recurrent genital herpes, Herpes simplex virus, 227
Guinea pig, Cytomegalovirus infection, Antiviral agent, Nucleoside analog, HPMPC, Cultured cell, 237

Herpes simplex virus, Oligonucleotide inhibition, 151
Herpes simplex virus type 1, Human monocyte, Differentiation, Interferon-α, Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
Herpes simplex virus, DNA polymerase inhibition, Phosphonylmethoxyalkylpurine,-pyrimidine, HPMPA, PMEA, 209
Herpes simplex virus, Acyclovir, Recurrent genital herpes, Guinea pig model, 227
Hg cells, HIV-1, DNA topoisomerase II activity, 273
HIV-1 p24 antigenemia, Asymptomatic HIV infection, Zidovudine treatment, 127
HIV-1, Hg cells, DNA topoisomerase II activity, 273
HPMPA, DNA polymerase inhibition, Herpes simplex virus, Phosphonylmethoxyalkylpurine,-pyrimidine, PMEA, 209
HPMPA, HSV-1 encoded ribonucleotide reductase, Phosphonylmethyl derivative of acyclic nucleoside analog, PMEA, 253
HPMPA, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivates, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPC, PMEA, 295
HPMPC, Cytomegalovirus infection, Antiviral agent, Nucleoside analog, Cultured cell, Guinea pig, 237
HPMPC, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivates, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, PMEA, 295
HSV, Immunotherapy, Liposome, Recurrence, Antigen presentation, 187
HSV-1 encoded ribonucleotide reductase, Phosphonylmethyl derivative of acyclic nucleoside analog, HPMPA, PMEA, 253
HSV-1, ()-BHCG, HSV-2, 43
HSV-2, ()-BHCG, HSV-1, 43
HSV-infected cell, (E)-5-(2-bromovinyl)-2′-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Antiherpes activity, dNTP pool, 111
Hu rIFN, FEAU, Simian varicella virus, Monkey, 165
Human CMV, Mouse CMV, Monkey CMV, CMV receptor, 1
Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon-α, Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
Hypericin, Anthraquinone, Anti-HIV-1 activity, Reverse transcriptase, 265
Hypericin, Pseudophypericin, Virucidal agent, Enveloped virus, Non-enveloped virus, 313
Immune modulator, Nucleoside analog, Guanosine analog, 91
Immunomodulator, Lipid A analogue, Interferon, Natural killer (NK) cell, 327
Immunotherapy, HSV, Liposome, Recurrence, Antigen presentation, 187
Influenza virus, Pine cone extract, RNA dependent RNA polymerase, Influenza, Nasal IgA, 103
Inhibition of RNA synthesis, 2-5 As, Dinucleotide, Vesicular stomatitis virus, RNA polymerase, 81
Interferon, Cat Mx protein, Feline viral disease, 53
Interferon-α, Human monocyte, Differentiation, Herpes simplex virus type 1, Poly I:C-LC, acyclovir, Viability index, Drug screening, 175
Interferon, Immunomodulator, Lipid A analogue, Natural killer (NK) cell, 327
Isobole method, Synergism, Antagonism, Antiviral combination experiment, Mathematical modeling, 23

Lipid A analogue, Immunomodulator, Interferon, Natural killer (NK) cell, 327
Liposome, Immunotherapy, HSV, Recurrence, Antigen presentation, 187

Mathematical modeling, Synergism, Antagonism, Antiviral combination experiment, Isobole method, 23
Measles virus, Cell-mediated immunity, 75
Monkey CMV, Human CMV, Mouse CMV, CMV receptor, 1
Monkey, FEAU, Hu rIFN, Simian varicella virus, 165
Mouse CMV, Human CMV, Monkey CMV, CMV receptor, 1

N-(2-phosphonylmethoxyethyl) derivative, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivates, Acyclic nucleotide analogue, HPMPA, HPMPC, PMEA, 295
N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivates, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, HPMPC, PMEA, 295
Nasal IgA, Influenza, 103
Natural killer (NK) cell, Immunomodulator, Lipid A analogue, Interferon, 327
Non-enveloped virus, Hypericin, Pseudophypericin, Virucidal agent, Enveloped virus, 313
dNTP pool, (E)-5-(2-bromovinyl)-2′-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Antiherpes activity, HSV-infected cell, 111

Nucleoside analog, Immune modulator, Guanosine analog, 91
Nucleoside analog, Cytomegalovirus infection, Antiviral agent, HPMPC, Cultured cell, Guinea pig, 237

Oligonucleotide inhibition, Herpes simplex virus, 151

Phosphonylmethyl derivative of acyclic nucleoside analog, HSV-1 encoded ribonucleotide reductase, HPMPA, PMEA, 253
Pine cone extract, Influenza virus, RNA dependent RNA polymerase, 11
Plant virus, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, TMV, PVX, 219
PMEA, DNA polymerase inhibition, Herpes simplex virus, Phosphonylmethoxyalkylpurine,-pyrimidine, HPMPA, 209
PMEA, HSV-1 encoded ribonucleotide reductase, Phosphonylmethyl derivative of acyclic nucleoside analog, HPMPA, 253
PMEA, N-(3-Hydroxy-2-phosphonylmethoxypropyl) derivates, N-(2-phosphonylmethoxyethyl) derivative, Acyclic nucleotide analogue, HPMPA, HPMPC, 295
PMEA, Reverse transcriptase, Retrovirus, Avian myeloblastosis virus, 287
Phosphonylmethoxyalkylpurine,-pyrimidine, DNA polymerase inhibition, Herpes simplex virus, HPMPA, PMEA, 209
Poly I:C-LC, acyclovir, Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon-α, Viability index, Drug screening, 175
Pseudophypericin, Hypericin, Virucidal agent, Enveloped virus, Non-enveloped virus, 313
PVX, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, Plant virus, TMV, 219

RNA dependent RNA polymerase, Influenza virus, Pine cone extract, 11
RNA polymerase, 2-5 As, Dinucleotide, Vesicular stomatitis virus, Inhibition of RNA synthesis, 81
Recurrence, Immunotherapy, HSV, Liposome, Antigen presentation, 187
Recurrent genital herpes, Acyclovir, Herpes simplex virus, Guinea pig model, 227
Retrovirus, Reverse transcriptase, PMEA, Avian myeloblastosis virus, 287
Reverse transcriptase, Anthraquinone, Anti-HIV-1 activity, Hypericin, 265
Reverse transcriptase, Retrovirus, PMEA, Avian myeloblastosis virus, 287
Rhesus monkey, Ribavirin, Dengue, 139
Ribavirin, Dengue, Rhesus monkey, 139
Ro 09-0410, Antirhinovirus agent, Chalcone amide, Binding site, Drug resitant HRV-2 subline, 61

SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, Plant virus, TMV, PVX, 219
Simian varicella virus, FEAU, Hu rIFN, Monkey, 165
Synergism, Antagonism, Antiviral combination experiment, Isobole method, Mathematical modeling, 23
Synthetic flavanoid, Astrovirus, 201

Tetrahydrodeoxyuridine (deaminase inhibitor), (E)-5-(2-bromovinyl)-2′-deoxycytidine, Anti-herpes activity, dNTP pool, HSV-infected cell, 111
TMV, SAH hydrolase inhibitor, (RS)-AHPA, (RS)-DHPA, C-c3Ado, Plant virus, PVX, 219

Vesicular stomatitis virus, 2-5 As, Dinucleotide, RNA polymerase, Inhibition of RNA synthesis, 81
Viability index, Human monocyte, Differentiation, Herpes simplex virus type 1, Interferon-, Poly I:C-LC, acyclovir, Drug screening, 175
Virucidal agent, Hypericin, Pseudophypericin, Enveloped virus, Non-enveloped virus, 313

Zidovudine treatment, Asymptomatic HIV infection, HIV-1 p24 antigenemia, 127